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Spinal muscular atrophy (SMA) is characterized by the loss of α-motoneurons (MNs) 
with concomitant muscle denervation. However, not all MNs are equally susceptible to 
degeneration in MN diseases, including SMA. This differential vulnerability has been 
linked to MN excitability, which can be modulated by cholinergic inputs via C-type 
synaptic boutons. Sigma-1 receptor (Sig1R) is expressed in MNs and particularly 
enriched in C-boutons. Alterations in Sig1R have been associated with MN 
degeneration. Here, we investigated whether a chronic treatment with the Sig1R agonist 
PRE-084 was able to exert beneficial effects on SMA. We used a model of intermediate 
SMA, the Smn2B/- mouse, in which we performed a detailed characterization of the 
histopathological changes that occur throughout the disease. We report that Smn2B/- mice 
exhibited qualitative differences in major alterations found in mouse models of severe 
SMA. In this respect, Smn2B/- animals exhibited more prominent MN degeneration with 
early motor axon alterations, marked changes in sensory neurons, and later MN 
deafferentation which correlated with conspicuous reactive gliosis and altered, 
neuroinflammatory, M1/M2 microglial balance. PRE-084 treatment attenuated reactive 
gliosis, mitigated M1/M2 imbalance and prevented MN deafferentation in Smn2B/- mice. 
These effects can also be observed in a severe SMA model, the SMNΔ7 mouse. 
However, the prevention of gliosis and MN deafferentation promoted by PRE-084 were 
not accompanied by any improvements in clinical outcome or other major pathological 
changes found in SMA mice. 
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Spinal muscular atrophy (SMA) is a genetic, autosomal recessive, neuromuscular 
disorder predominantly characterized by a progressive loss of α-motoneurons (MNs), 
atrophy of skeletal muscles and motor impairment (1). With an incidence of 1 in 6,000-
10,000 live births and a carrier frequency of 1 in 35-50 (2, 3), this disease is the leading 
genetic cause of infant mortality. SMA is caused by deletion or inactivating mutations 
of the survival motor neuron 1 (SMN1) gene located in the telomeric position of 
chromosome 5q13 (4). SMN1 is ubiquitously expressed and plays an important role in 
mRNA splicing by orchestrating small nuclear ribonuclear protein complex assembly 
(5). Humans possess an almost identical copy of SMN1, referred to as SMN2; which is 
also located on chromosome 5, but in its centromeric region. SMN2 differs from SMN1 
in terms of an exon 7 C-to-T transition. This change alters the normal splicing of 
mRNA and leads to the production of ~85-90% SMN2 transcripts that lack exon 7. 
When these transcripts are traduced, a truncated and unstable protein (SMN∆7) is 
produced (6), resulting in inefficient levels of functional, full-length (FL), SMN protein. 
Depending on the age of onset and the severity of disease, SMA can be clinically 
classified into several different types; these range from type I (the severest form) to type 
IV (the mildest form). The severity of the disease is inversely correlated with the SMN2 
copy number (7, 8). Thus, the most severely affected patients are usually the ones with 
the fewest copies of SMN2. 
Since the identification of the loss-of-function defects in SMN1 gene as the cause of 
SMA, intensive efforts have been made to develop experimental therapeutic approaches 
to increase SMN protein (see for reviews (9-12)). Small molecules, such as antisense 
oligonucleotides (ASOs), which promote SMN2 exon 7 inclusion and thereby increase 
FL SMN2 transcription, and viral gene therapies, which directly replace SMN1, are 
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promising strategies for SMA. In this regard, the ASO Nusinersen, which acts as a 
splicing modifier targeting the intronic splicing silencer N1 in SMN2 intron 7 (13), has 
been recently approved for SMA treatment. Clinical trials have shown that Nusinersen 
administration results in a significant improvement in motor function and survival of 
type I SMA infants (14-17). Even so, there is still a need for complementary, SMN-
independent, approaches which target cellular and molecular elements that are disturbed 
by the SMN deficiency. These therapies, used in synergy with SMN-targeted strategies, 
appear to be important for the long-term preservation of the neuromuscular structure 
and function (12). 
The reason why insufficient levels of SMN protein predominantly lead to MN loss is 
still unclear (18). Moreover, it is known that, in the case of MN diseases, not all MNs 
exhibit a similar susceptibility to degeneration: while some MNs degenerate early, 
others remain apparently undamaged until the end-stages. This differential vulnerability 
of different MN subtypes appears to be related to their excitability (19). The highly 
organized pattern of MN activity and excitability is modulated by cholinergic inputs 
delivered through C-type synaptic boutons. C-boutons may therefore be ultimately 
related to MN susceptibility to degeneration (20, 21). 
C-boutons exhibit a highly specialized postsynaptic organelle known as subsurface 
cistern (SSC), which is closely related to the endoplasmic reticulum (ER) lamellae and 
adjacent to the postsynaptic membrane (22). The molecular organization of C-boutons 
includes: M2 muscarinic receptors (23), voltage-gated K+ channels (Kv2.1) and Ca2+-
activated K+ channels (SK) (24, 25), sigma-1 receptors (Sig1Rs) (26), and neuregulin-1 
(NRG-1) (27). All of these molecules seem to be clustered together in specific 
microdomains. However, the role of some of them, including Sig1R and NRG-1, in C-
bouton regulation still remains unknown. 
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The Sig1R is a transmembrane protein with chaperone-like activity, which is widely 
distributed in mammalian central and peripheral nervous systems. This protein is mainly 
located in the ER. Sig1R is particularly enriched in a sub-region of the ER in which 
their cisternae come into contact with mitochondria; this point of contact is known as 
the mitochondrion-associated ER membrane (MAM) (28). Sig1R, which acts as an 
inter-organelle signaling modulator, is involved in several cellular processes which 
include the regulation of ER-mitochondrion signaling and ER-nucleus crosstalk (29). 
Sig1R also appears to play a role in unfolded protein response control and in the 
protection of cells from both oxidative and ER-mediated cellular stress (30). Following 
ligand stimulation, Sig1R can also translocate from the MAM to other parts of the cell. 
Sig1R can therefore interact with several different ion channels, receptors and/or 
kinases in the plasma membrane (31). In neurons, Sig1R mediates the regulation of 
several different processes, such as neuritogenesis, K+ channel and N-methyl-D-
aspartate (NMDA) receptor activity and Ca2+ homeostasis (31-33). Sig1R stimulation 
has also been shown to modulate multiple aspects of microglial activity (34-36). 
Mutations of the Sig1R gene are related to MN disorders, such as amyotrophic lateral 
sclerosis (ALS) (37, 38). Moreover, a lack of Sig1R exacerbates ALS progression in a 
mouse model of the disease (39). The synthetic Sig1R agonist 2-(4-morpholinethyl)1-
phenylcyclohexanecarboxylate (PRE-084) has been reported to confer neuroprotection 
after excitotoxic stimuli in vitro (40) and after spinal root avulsion in rats (34). 
Furthermore, the administration of PRE-084 in the SOD1G93A mouse model extends 
survival and improves motor function by preventing MN death and preserving 
neuromuscular connections (41). More recently, the neuroprotective effects of PRE-084 




In the present study we wanted to investigate whether chronic treatment with PRE-
084 was able to elicit beneficial effects on SMA. To check this, we used the Smn2B/- 
mouse, a model for intermediate SMA (43, 44), whose lifespan is prolonged until about 
25-30 days and in which the phenotypic features of disease are more gradual than in 
murine models for severe SMA (e.g. Smn-/-;SMN2+/+ or SMNΔ7 mice). We started by 
examining the progression of pathological changes in the spinal cord, dorsal root 
ganglion, motor and sensory nerves, and neuromuscular junctions (NMJs) of Smn2B/- 
mice throughout the disease. These changes were correlated with motor disabilities in 
mice. Here, we show that, in comparison with severe SMA mouse models, the Smn2B/- 
mouse exhibited substantial differences in the degree and time-course of MN 
degeneration and deafferentation. We also report that the PRE-084 treatment in Smn2B/- 
robustly prevented reactive gliosis in the spinal cord and restored the altered microglial 
phenotypic (M1/M2) balance associated with SMA. This effect of PRE-084 mitigating 
gliosis was also reproduced in SMNΔ7 mice. Although PRE-084 partially prevented the 
loss of afferent inputs to MNs linked to SMA, it was, however, unable to prevent MN 
degeneration. PRE-084 was also able to improve neurofilament (NF) accumulation in 
motor nerve terminals, but failed to ameliorate other major pathological changes found 
at the neuromuscular junctions (NMJs) in SMA mice. Furthermore, no improvement in 
survival or motor abilities was observed in SMA animals treated with PRE-084. 
MATERIALS AND METHODS 
Mice and pharmacological experiments with PRE-084 
The SMNΔ7 and Smn2B/- mouse lines were used. To generate SMNΔ7 animals, Smn+/-
;SMN2+/+;SMNΔ7+/+ mice (heterozygote knockouts for the Smn gene, FVB.Cg-
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Tg[SMN2*delta7]4299Ahmb Tg[SMN2]89Ahmb Smn1tm1Msd/J, stock number 
005025) were purchased from The Jackson Laboratory (Sacramento, CA, USA); 
heterozygous female and male animals were crossed to obtain Smn-/-
;SMN2+/+;SMNΔ7+/+ (homozygote knockouts for the Smn gene, referred as SMNΔ7) 
and Smn+/+;SMN2+/+;SMNΔ7+/+ (wild-type for the Smn gene, hereafter referred as WT) 
mice. 
The Smn2B/- mice (C57BL/6 background) were obtained by crossing heterozygote 
knockout for the Smn gene (Smn+/- [B6.Cg-Smn1tm2Mrph/J, stock 007963], The Jackson 
Laboratory) males with homozygote for the 2B mutation (Smn2B/2B) females, which 
were a kind gift from Dr Rashmi Kothary (University of Ottawa, Canada). The 2B 
mutation consists of a substitution of three nucleotides in the exon splicing enhancer of 
exon 7 (45). Smn2B/+ heterozygous mice do not exhibit any apparent SMA phenotype 
(46) and were therefore used as controls (hereafter referred to as WT). 
SMNΔ7 mice exhibit a severe postnatal SMA phenotype, with overt symptomatology 
and pathological changes in the spinal cord and skeletal muscles at 7-8 days after birth, 
and have a mean lifespan of about 2 weeks (47-50). Smn2B/- animals develop a milder 
postnatal SMA phenotype, with a lower growth-related gain in body weight from about 
postnatal day (P) 12, and neuromuscular histopathological alterations and motor 
function deficits at about P16-17; Smn2B/- animals have a mean lifespan of about 3-4 
weeks ((46, 51) and our own observations). 
At P0, a piece of tail was removed from the mice for subsequent genotyping. The 
REDExtract-N-Amp Tissue PCR Kit (Sigma, St Louis, MO) was used for genomic 
DNA extraction and polymerase chain reaction setup. To distinguish between SMNΔ7 
mice and their WT littermates, the following primers were used: WT forward 5’ 
ctccgggatattgggattg 3’, SMNΔ7 reverse 5’ ggtaacgccagggttttcc 3’ and WT reverse 5’ 
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tttcttctggctgtgccttt 3’. To identify Smn2B/- mice, the gene that had to be detected was 
lacZ; this was used to interrupt the Smn murine gene (52). The primers used were: lacZ 
forward 5’ ttggcctgaactgccagctggcgcagg 3’ and lacZ reverse 
5’tcccgcagcgcagaccgttttcgctcg 3’. Electrophoresis in 1.5% agarose gel and SYBR safe 
DNA stain (Molecular Probes, Eugene, OR) was run at 100 V. 
WT and SMA (SMNΔ7 or Smn2B/-) mice were treated with either PRE-084 (Tocris 
Bioscience, Bristol, United Kingdom; 0.25 mg/Kg/day) or the corresponding volume of 
physiological saline solution (vehicle). The PRE-084, or vehicle, was administered once 
a day, in the morning from P1 until the end of the experimental time frame, via 
subcutaneous interscapular injections. The dosage, regimen and mode of PRE-084 
administration used here were similar to those used in previous studies (41, 42). At 
selected points in time, the mice were anaesthetized with an intraperitoneal injection of 
pentobarbital (2%, 1 ml/10 g body weight), and transcardially perfused with 
physiological saline solution, followed by 4% paraformaldehyde (PFA) in 0.1 M 
phosphate buffer (PB) at pH 7.4. Mice used for electron microscopy studies were 
perfused with a solution containing 1% PFA and 1% glutaraldehyde in 0.1 M PB at pH 
7.4. Tissue samples were rapidly dissected, removed, and subsequently processed as 
indicated below. All the experimental procedures were carried out according to the 
guidelines of the committee for Animal Care and Use of the University of Lleida, which 
have been approved by the Generalitat de Catalunya. 
Behavioral phenotype testing 
To evaluate disease progression, the mice were weighed every morning and carefully 
examined in order to detect the presence of any specific signs and/or symptoms of 
disease. Thereafter, the righting reflex and hind-limb suspension test (“tube test”) were 
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conducted to assess the motor abilities of the SMNΔ7 mice from P0-1 until their death, 
and Smn2B/- mice from P0-1 to P10. These tests were scored following the guidelines 
described elsewhere (50, 53). 
From P10, the motor behavior of Smn2B/- mice was assessed by performing tests to 
analyze their motor balance and muscular strength: pen test and grip test. For the pen 
test, mice were placed on a suspended rope, as previously described (54). The latency to 
fall and the number of hindlimbs that mice were capable of grasping on the rope (2, 1 or 
0) were measured. For the grip test, mice were placed on a surface whose slope was 
progressively increased; we noted the maximum slope that the mice were able to remain 
on for a period of 20 seconds without falling (55). 
Tests were conducted by the same investigator (who was blind to the experimental 
condition). In each test, each individual mouse was examined three times, with a 15-
minute recovery period between tests. The average values from the three independent 
tests were then determined in order to obtain the final score. 
Muscle and spinal cord histology and MN counts 
Tibialis anterior (TA) and intercostal (IC) muscles, and spinal cords were rapidly 
dissected and removed for subsequent histological analysis and MN counting. 
Muscles were weighed, postfixed in 4% PFA in 0.1 M PB (pH 7.4), cryoprotected 
with 30% sucrose in 0.1 M in PB, embedded in Tissue Freezing Medium (TFM, 
Triangle Biomedical Sciences, Durham, NC, USA), and then frozen. Multiple cryostat 
transverse sections (16-μm thick) were obtained from the mid-belly of the muscle. 
Sections were subsequently stained with hematoxylin and eosin (H&E). 
For MN counts, spinal cords were fixed in Bouin’s solution and embedded in 
paraffin. Serial transverse sections (14-μm thick), obtained throughout the entire lumbar 
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segment, were stained with H&E. Apparently healthy MNs present in the ventral horn 
were identified by their size and shape and counted blindly on one side of every 10th 
section, following previously described procedures (56, 57). Briefly stated, only MNs 
with a large nucleus, a visible clump of nuclear material and a substantial cytoplasm 
were counted. The total number of MNs per ventral horn was obtained by multiplying 
the number of cells counted by 10. 
Immunocytochemistry and imaging 
For immunocytochemical studies, TA and IC muscles, lumbar spinal cords and L4 
dorsal root ganglia (DRGs) were postfixed by immersion in 4% paraformaldehyde in 
0.1 M PB, at pH 7.4, either for 2 hours (in the case of muscles) or overnight (in the case 
of spinal cords and DRGs), and then cryoprotected. Tissue samples were embedded in 
TFM and frozen. Longitudinal (for muscles, 16-μm thick) and transverse (for spinal 
cords and DRGs, 14-μm thick) serial cryostat sections were obtained and then stored at 
-80ºC. 
Sections were sequentially rinsed for 30 minutes in phosphate-buffered saline (PBS) 
containing 0.1% Triton X-100, then blocked in normal goat serum or normal horse 
serum, and subsequently incubated overnight with the chosen primary antibody. The 
following primary antibodies were used: goat polyclonal anti-matrix metalloproteinase-
9 (MMP-9; diluted 1:10; Sigma-Aldrich, Madrid, Spain; catalog no. M9570) rabbit 
polyclonal anti-ionized calcium-binding adaptor molecule 1 (IBA1, diluted 1:500; 
Wako Pure Chemical Industries Ltd., Osaka, Japan; catalog no. 019-19741); chicken 
polyclonal anti-glial fibrillary acidic protein (GFAP, diluted 1:1000; Abcam, 
Cambridge, UK; catalog no. Ab4674); chicken polyclonal anti-neurofilament 68 KDa 
(NF, diluted 1:1000; Abcam; catalog no. ab72997); mouse monoclonal anti-synaptic 
vesicle protein 2 (SV2; diluted 1:1000; Developmental Studies Hybridoma Bank 
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[DSHB], Iowa City, IA; catalog no. SV2); rat monoclonal anti-Mac-2 (diluted 1:800; 
Cedarlane, Burlington, Canada; catalog no. CL8942AP); goat polyclonal anti-CD206 
(diluted 1:100; RD Systems, Minneapolis, MN; catalog no. AF2535); rabbit polyclonal 
anti-NRG1 (diluted 1:100; Santa Cruz; catalog no. sc-348); mouse monoclonal anti-
Sig1R (diluted 1:50; Santa Cruz; catalog no. sc-137075); guinea pig polyclonal anti-
vesicular acetylcholine transporter (VAChT, diluted 1:300; Synaptic Systems, 
Goettingen, Germany; catalog no. 139105); guinea pig polyclonal anti-vesicular 
glutamate transporter 1 (VGluT1, diluted 1:500; Synaptic Systems; catalog no. 135304); 
guinea pig polyclonal anti-vesicular GABA transporter (VGAT, diluted 1:200; Synaptic 
Systems; catalog no. 131004); rabbit polyclonal anti-NMDA NR1 subunit (NR1, diluted 
1:250; Abcam; catalog no. ab17345); rabbit polyclonal anti-phospho NR1 (Ser897) (p-
NR1, diluted 1:500; Millipore; catalog no. ABN99); rabbit polyclonal anti-calcitonin 
gene-related peptide (CGRP, diluted 1:1000; Sigma-Aldrich; catalog no. C8198); and 
mouse monoclonal anti-parvalbumin (PV, diluted 1:5000, Swant, Marly, Switzerland; 
catalog no. PV 235). 
After incubation with the primary antibody, the sections were washed and then 
incubated at room temperature (RT) for 1 hour with the appropriate secondary 
fluorescent antibodies: DyLight 488-conjugated donkey anti-rabbit IgG; DyLight 549-
conjugated donkey anti-rat or anti-chicken IgG; DyLight 649-conjugated donkey anti-
mouse or anti-chicken IgG; Cy3-conjugated donkey anti-rabbit, anti-mouse or anti-goat 
IgG (all diluted 1:500, from Jackson ImmunoResearch Laboratories, West Grove, PA); 
and Alexa Fluor 488-conjugated goat anti-chicken IgG and Alexa Fluor 647-conjugated 
donkey anti-guinea pig IgG (diluted 1:500; Molecular Probes). Sections were also 
stained with 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI, 50 ng/ml, 
Molecular Probes) for DNA labeling. Muscle sections were also incubated with Alexa 
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Fluor 488-conjugated α-bungarotoxin (α-Bgtx, diluted 1:500; Molecular Probes) to 
identify postsynaptic acetylcholine receptors. Spinal cord sections were counterstained 
with NeuroTrace 530/615 red or NeuroTrace 435/455 blue fluorescent Nissl stain 
(Molecular Probes). Some slides with DRG sections were stained with the FITC-
conjugated Bandeiraea simplicifolia lectin (isolectin B4, IB4, diluted 1:25; Sigma-
Aldrich). After washing, slides were coverslipped using Vectashield (Vector 
Laboratories, Burlingame, CA) or Mowiol (Calbiochem, San Diego, CA). Slides were 
examined with an Olympus BX51 epifluorescence microscope (Olympus, Hamburg, 
Germany) equipped with a DP30BW camera or FluoView 500 or FluoView 1000 
Olympus laser scanning confocal microscopes. For comparisons, slides from different 
animals and experimental conditions were processed in parallel for 
immunocytochemistry and subsequent imaging. The same scanning parameters were 
used for the acquisition of images corresponding to different experimental groups. For 
spinal cord immunocytochemical studies, digital images of the entire lumbar region 
were obtained from every 30th section. 
Electron microscopy 
Ventral and dorsal nerve roots (VRs and DRs, respectively) were separately 
dissected, postfixed in 1% osmium tetroxide, and embedded in EMbed 812 (Electron 
Microscopy Sciences, Fort Washington, PA) epoxy resin, following standard 
procedures. Semithin sections (1-ߤm thick) stained with methylene blue were examined 
and imaged using an Olympus 60X/1.4 NA PlanApo oil immersion objective (Olympus, 
Hamburg, Germany) and a DMX 1200 Nikon (Tokyo, Japan) digital camera. Ultrathin 
sections were counterstained with uranyl acetate and lead citrate and then observed in a 
Zeiss EM 910 (Zeiss, Oberkochen, Germany) electron microscope. 
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Image and morphometric analysis 
The cytoarchitecture of the NMJs was analyzed in longitudinal immunostained 
sections of muscle. Z-stack optical sections (1 μm-thick) were obtained and projected to 
reconstruct NMJs using microscope software. Five to nine sections were analyzed for 
each muscle and animal, and 50-75 NMJs from randomly selected visual fields were 
evaluated for each experimental condition. NMJ size was assessed by determining the 
area of the α-Bgtx-labeled postsynaptic site, which was manually outlined using ImageJ 
software (National Institutes of Health, USA). A NMJ was considered to be denervated 
when the percentage of α-Bgtx-labeled postsynaptic surface covered by the SV2-stained 
presynaptic terminal was less than 15% (50, 58). Based on the structural appearance of 
each postsynaptic site, the degree of NMJ maturity was classified as: plaque, folds, 
perforations, or secondary structure (pretzel-like morphology), with this ranging from 
immature to mature, according to previously described criteria (50, 58). NF was 
considered to accumulate in the presynaptic sites when the terminal portion of axons 
exhibited a swollen morphology and was strongly stained with the anti-NF antibody. 
Any NMJs that were difficult to analyze due to their location and/or orientation were 
excluded from the analysis. 
Levels of GFAP and IBA1 immunoreactivitity in the spinal cord were quantified by 
digital image analysis using ImageJ software. The number of NRG-1- and Sig1R-
immunolabeled profiles, and VAChT, VGluT1 and VGAT immunoreactive synaptic 
boutons on MN somata was counted on the screen; only boutons that were in close 
contact with MNs exhibiting a large nucleus, visible nucleolus and healthy appearance 




The number and soma area of CGRP, IB4 and PV immunopositive sensory neurons 
in the DRGs were measured using digital images taken from cryostat sections and 
ImageJ software. The area of DRG neurons was also assessed in sections counterstained 
with NeuroTrace fluorescent Nissl stain (Molecular Probes). 
Axon diameter and g-ratio measurements were performed on electron micrographs of 
VRs and DRs taken from mice at different points in time. For g-ratio analysis, we used 
the ImageJ g-ratio plug-in; this allowed us to obtain semiautomated measurements of 
randomly selected nerve fibers. The axon diameter was divided by the outer diameter of 
the myelin sheath. At least 100 myelinated axons per mouse (3 mice per condition) were 
measured. The number and diameter of healthy and degenerating myelinated axons was 
determined from 60X images taken from VR and DR cross semithin sections stained 
with methylene blue. The images were joined together to obtain a whole picture of a 
complete nerve root transverse section. The diameter of the myelinated axons was 
measured by delineating the outer profile of the myelin sheath. 
Western blotting 
Frozen spinal cords were fragmented and homogenized with blending buffer 1 x SR 
(2% SDS and 125 mM Tris-HCl, pH 6.8) supplemented with protease inhibitor (Sigma, 
Ref. P8340) and PhosSTOP (Roche, Laval, Canada). The homogenized samples were 
then heated to 100 ºC for 5 minutes and centrifuged at 12,000 rpm for 5 minutes. The 
protein concentrations of supernatants were determined by BIO-RAD Micro DC protein 
assay (BIO-RAD, Laboratories Inc., Hercules, CA, USA). Loading buffer 4 x SS (20% 
sucrose and 0.05% bromophenol blue, 0.1% sodium azide) containing 5-10% β-
mercaptoethanol (Sigma) and 15 μg of protein was then loaded into a 10% or 15% 
polyacrylamide electrophoresis gel. Proteins were electrotransferred to PVDF 
(ImmobilonTM-P, Millipore, Bredford, MA, USA) membranes in a Tris-glycine-
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methanol-buffered solution. The membranes were then blocked with 5% dried skimmed 
milk in 0.1% Tween 20 and Tris-buffered saline pH 8 (TBST) for 1 hour at RT, and 
then extensively washed in TBST. Immunodetection was performed by incubating the 
membranes overnight at 4ºC with the following antibodies: rabbit polyclonal anti-NR1 
(diluted 1:250; Abcam); rabbit polyclonal anti-p-NR1 (Ser897, diluted 1:500; 
Millipore); mouse monoclonal anti-SMN (diluted 1:1000; BD Biosciences, San Jose, 
CA, USA; catalog no. 610647); mouse monoclonal anti-β-actin (diluted 1:1000; Sigma; 
catalog no. A54441). The antibody against β-actin was used for loading controls. The 
membranes were washed in TBST, incubated for 60 min at RT with the appropriate 
peroxidase-conjugated secondary antibodies (1:5000; Amersham Biosciences, 
Buckinghamshire, UK), washed in TBST, and visualized using the ECL Prime Western 
Blotting Detection Reagent detection kit (GE Healthcare, Buckinghamshire, UK), 
following the procedure described by the manufacturer. The quantification of band 
densities was performed by using Chemi-Doc MP Imaging System (BIO-RAD 
Laboratories Inc.). 
Statistical analysis 
Data were expressed as means ± SEM. The statistical analysis was assessed by either 
one- or two-way analysis of variance (ANOVA) followed by post-hoc Bonferroni’s 
multiple comparison test or Student’s t-test when only two different groups were 
compared. Differences were considered to be statistically significant if p ≤ 0.05. 
RESULTS 
Behavioral alterations, MN loss and motor axon degeneration in Smn2B/- mice 
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With the progression of disease, SMA mice exhibit less body-weight gain than their 
WT littermates and suffer gradual impairment of their motor performance, as reported 
for different types of murine models (48). Smn2B/- mice develop a milder form of the 
disease, with phenotypic changes and motor deficits occurring more gradually than in 
other extensively used SMA mouse models (51). In line with previous reports (59), in 
Smn2B/- animals, we did not find any significant reduction in body weight or any 
apparent alterations in motor abilities until P12-14, with a mean lifespan of about 28 
days (not shown). The changes in motor performance and survival in Smn2B/- mice 
observed in our study during the progression of disease are shown in supplementary 
Fig. 1a-e. 
We first characterized the time of onset and the degree of MN death during the 
course of disease in the Smn2B/- mice. Apparently healthy MNs were counted on H&E-
stained transverse serial sections of the entire, paraffin-embedded, spinal cord lumbar 
segment, according to established criteria (56, 57). In contrast to the moderate MN loss 
found in the lumbar spinal cord of different mouse models of severe SMA (i.e. Smn+/-
;SMN2+/+ or SMNΔ7 mice (49, 60)), Smn2B/- animals undergo progressive and 
prominent MN degeneration (Fig. 1A). In this model, a depletion of MNs had already 
been observed at P5, but was even more marked and significant at P10 (~30% of WT 
mice). Interestingly, and as mentioned above, at none of these ages did we detect any 
perceptible alterations in motor behavior in diseased animals. A still more dramatic fall 
in the number of MNs was seen at P20 (~75% of WT animals), followed by only a 
minor additional MN loss during the end-stage of disease (from P20 to P25-30). Smn2B/- 
MNs also displayed a significant size reduction, which had already been noticeable at 
P5; this became particularly marked at P10 (~55% of WT MNs), but then barely 
changed from P10 to P25-30 (Fig. 1B). The appearance of MNs in the lumbar spinal 
17 
 
cord of WT and Smn2B/- mice is shown in Fig.1C-G. In diseased animals, the scarce 
MNs which remained in the ventral horn at end-stages displayed an abnormal 
morphology compatible with ongoing cell degeneration. Some of these degenerating 
MNs appeared surrounded of nuclear profiles which probably correspond to microglia 
recruited by the sick cell (Fig. 1G). 
Several studies have reported the differential vulnerability of spinal MNs to 
degeneration in ALS (61, 62). MNs innervating slow-twitch muscles (slow MNs) are 
therefore more resistant than those innervating fast-twitch muscles (fast MNs). In 
particular, fast-fatigable MNs are the ones most severely affected and which degenerate 
earliest during disease; they are followed by fast-fatigue resistant and slow MNs, which 
persist until later stages of disease. To determine whether the vulnerability of fast MNs 
is also a feature of SMA, we performed an immunocytochemical analysis of MMP-9 
expression in the lumbar spinal cord of WT and Smn2B/- mice. MMP-9 has been shown 
to be selectively expressed in fast MNs prior to the onset of ALS disease in SOD1 mice 
(63). We did not find any signs of MMP-9 immunoreactivity in the spinal MNs of either 
WT or diseased animals at P1. However, as shown in Fig. 1H and I-N’, at P5 ~58% of 
WT MNs exhibited MMP-9 positive immunolabeling, whereas this was observed in 
~40% of the surviving Smn2B/- MNs (~18% reduction vs. WT, p<0.05). The percentage 
of MNs showing MMP-9 expression then fell to ~17% in Smn2B/- mice at P20 (~48% 
reduction vs. P20 WT, p<0.001). Taking into account the fact that Smn2B/- mice showed 
~16% fewer MNs than age-matched WT littermates at P5, overall, these results suggest 
a preferential loss of fast-fatigable MNs during the early stages (P5) of disease in the 
Smn2B/- mice; the degeneration this MN subtype progresses until end-stages of SMA. 
It has been hypothesized that MN death in SMA is a consequence of a retrograde 
“dying-back” degeneration of motor axons which occurs at postnatal ages (64). This 
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would imply that pathological changes would start in the distal part of the motor axons 
and/or NMJs, and progress to MN cell bodies. To explore whether or not axonal 
alterations preceded MN death, L4 VRs taken from WT and Smn2B/- mice at different 
ages were embedded in plastic resin and then transversal sections were examined after 
methylene blue staining. As shown in Fig. 2A, the VRs from WT animals exhibited a 
progressive increase in myelinated axon diameter (including the myelin sheath) during 
the whole postnatal period; this reflected the maturation process of the motor nerves. In 
contrast, in the VRs of Smn2B/- mice, this normal axonal growth was significantly 
reduced at P25-30 (Fig. 2A and B). At all the time points studied, VRs from diseased 
mice contained fewer healthy myelinated axons than those from WT littermates (not 
shown). Moreover, a significant increase in the number of degenerating axons was 
observed in the VRs of Smn2B/- mice from P20 onwards (Fig. 2C-K). Interestingly, we 
noticed that at P5 about 5% of the myelinated axons in Smn2B/- VRs exhibited spheroidal 
masses resembling myelin ball structures, which were hardly ever seen in WT VRs (Fig. 
2L and M). The ultrastructural analysis of VRs at P5 revealed that the vast majority of 
axons in WT animals exhibited a normal appearance Fig. 3A,B). We only occasionally 
found some axons in WT VRs that showed structural regressive abnormalities (Fig. 3B); 
this was probably the result of a physiological remodeling process taking place in the 
motor nervous system during the early postnatal period of development (65-68). 
Conversely, a significant number of motor axons in Smn2B/- animals exhibited inclusions 
in the form of myelin-like multilaminar structures similar to those observed during 
Wallerian degeneration; in some cases, such myelin debris had been engulfed by 
phagocytic cells (Fig. 3C-F). Additionally, the axon diameter, determined by 
delineating the axon periphery under the myelin sheath, was found to be significantly 
longer in the VRs of Smn2B/- mice than in those of their WT littermates; this would seem 
19 
 
to indicate the presence of motor axon swelling in the SMA (Fig. 3G). Conversely, the 
myelin in motor axons of diseased animals was significantly thinner (g-ratio: 0.69 ± 
0.01, n = 100-125 per animal) than that in motor axons of WT mice (g-ratio: 0.63 ± 
0.01, n = 100-123 per animal) (Fig. 3H). Fig. 3I shows a scatter plot displaying g-ratios 
as a function of axon diameter: all of the axons in VRs from diseased animals showing 
higher size corresponded to those with higher g-ratios (implying thinner myelin). On the 
other hand, the Schwann cells enwrapping axons in healthy animals appeared to be 
more mature than those observed around degenerating axons in Smn2B/- mice (Fig. 3A 
and D-F). Overall, these data point to the expected existence of progressive atrophy and 
degeneration of motor axons as SMA progresses. Although in SMA animals this motor 
axon degeneration is not statistically significant until P20 (coinciding with both 
prominent MN loss and marked motor disabilities), axonal morphological alterations are 
already present at P5; these alterations include: swelling, hypomyelination and 
Wallerian-like degeneration, and correlate with the incipient MN death found at the 
same time point of disease. 
Changes in DRG cells and DR axons in Smn2B/- mice 
Sensory defects have been reported to occur in humans in the most severe forms of 
SMA (type I), but not in type II or III SMA (69-71). It has been shown that DRG 
sensory neurons are also affected in Smn-/-;SMN2 mice, which are a model for human 
type I SMA (72). To explore whether DRG neurons of Smn2B/- mice also displayed 
pathological changes, L4 DRGs from WT and SMA mice were taken at P20, an age at 
which, as previously mentioned, we had observed massive MN degeneration. DRG 
cryostat sections were processed for immunocytochemistry using antibodies against 
CGRP and PV, and stained with IB4, as specific markers for different neuronal 
subpopulations: CGRP is present in peptidergic sensory nociceptive neurons, which are 
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small and unmyelinated; IB4 exclusively stains non-peptidergic sensory nociceptive 
neurons, which are small and unmyelinated; and PV is localized in large sensory 
proprioceptive neurons that innervate muscle spindles (73-75) (Fig.4A-Q’’). DRGs of 
Smn2B/- mice showed a significant decrease in neuron soma size in relation to that 
observed in DRGs of WT littermates (Fig. 4A and B). Although we did not note any 
significant changes in the number of neurons expressing CGRP or IB4 in the DRGs of 
Smn2B/- animals (Fig. 4C and F), the size of these cell subpopulations was notably 
reduced (Fig. 4D,E and G,H). Conversely, PV immunoreactive neurons in Smn2B/- 
DRGs did not display any change in size (Fig. 4J,K) but their number significantly 
decreased (~45% reduction) in relation to that in WT DRGs (Fig. 4I). These data 
indicate a marked loss of proprioceptive neurons and atrophy of nociceptive 
subpopulations in the DRG linked to SMA. 
We next examined whether alterations in Smn2B/- DRG neurons were accompanied 
by sensory axon defects. L4 DRs, obtained from WT and Smn2B/- mice at different time 
points, were embedded in plastic resin and transversely sectioned. During the early 
stages of disease (P5 and P10) no phenotypic changes were seen in the sensory axons of 
Smn2B/-. However, from P20 onwards, we noted a significant reduction in the DR area in 
SMA animals (Fig. 5A-C). The number of axons in the DRs was then counted at the 
end-stage of disease (P25-30). Although moderate axonal loss was found in Smn2B/- 
DRs, this change did not reach a statistically significant level (Fig. 5D). Conversely, 
compared to WT littermates, Smn2B/- mice exhibited a significant decline in the diameter 
of sensory axons (Fig. 5E-H). The absence of noticeable sensory axon loss in Smn2B/- 
animals could be due to the fact that PV positive proprioceptive neurons, which we 
found in smaller numbers in SMA, represent only a small proportion (~13%) of the total 
number of L4 DRG neurons (76). On the other hand, the reduction in size of the sensory 
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axons observed in SMA mice could result from the cell atrophy observed in other 
subpopulations of DRG neurons (e.g. CGRP- and IB4-positive neurons). 
Reactive gliosis in the spinal cord and MN deafferentation in Smn2B/- mice 
Astroglial and microglial reactions in the ventral horn of spinal cord are changes linked 
to SMA in humans (38, 77-80) and severe murine models, including SMNΔ7 (49, 50, 
60, 80, 81). To study whether glial activation also occurs in the spinal cord of Smn2B/- 
mice, we analyzed astroglia and microglia after immunolabeling for GFAP and IBA-1, 
respectively. Diseased animals showed a progressive astrocytic reaction and prominent 
microgliosis around MNs. In relation to the ventral horns of WT animals, those of 
Smn2B/- mice at P20 showed an increase in GFAP positive profiles which peaked at P25-
30; spinal cords of Smn2B/- animals also exhibited a significantly higher density of IBA1 
positive microglia at P20, with only a slight reduction at P25-30 (supplementary Fig. 
2A-H). 
SMA progression is accompanied by functional and structural alterations in the 
sensory-motor connectivity, resulting in MN hyperexcitability (27, 49, 82-85). We 
therefore sought to analyze any changes in afferent synapses on the MNs of the Smn2B/- 
mice. To do this, the density of synaptic boutons on the MN somata was quantified in 
the lumbar spinal cord of WT and diseased animals at different time points. 
Glutamatergic excitatory and GABAergic inhibitory synapses were identified using 
antibodies against VGluT1 and VGAT. We found a gradual reduction in the density of 
both types of synapses as disease progressed. Compared to age-matched WT animals, 
the number of VGluT1 synapses on the MNs of Smn2B/- mice was significantly reduced 
at P20 and, more prominently, at P25-30 (supplementary Fig. 2I-O). The density of 
VGAT-positive synapses on Smn2B/- MNs was seen moderately, although significantly 
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increased at P10. After this age, the VGAT-afferent density on Smn2B/- MNs 
progressively declined, and therefore at P25-30 it was markedly lower than on WT MNs 
(supplementary Fig 2P and Q-V). The dramatic loss of VGAT-immunoreactive boutons 
at the end-stages in Smn2B/- mice contrasts with previous findings in the SMNΔ7 model, 
in which no reduction in the number of inhibitory inputs on MNs has been found at the 
late-symptomatic stages (49, 82). 
The potential changes in cholinergic inputs (C-bouton synapses) to MNs in SMA 
have been less explored (86). C-boutons were immunolabeled using an anti-VAChT 
antibody. WT mice were found to display a progressive postnatal increase in the 
number of C-boutons on MNs (Fig. 6A). Whereas MNs of both Smn2B/- and WT mice 
exhibited similar densities of C-boutons from P5 to P20, a dramatic loss of this type of 
synapse was observed in Smn2B/- MNs at P25-30 (Fig. 6A); indeed, at this age, MNs of 
diseased animals appeared to be almost devoid of cholinergic inputs (Fig. 6B-I). This C-
bouton depletion in Smn2B/- MNs was not, however, accompanied by any change in their 
synaptic size (C-bouton area at P25-30 expressed in μm2: WT = 3.70±0.20, Smn2B/- = 
3.72±0.14; p>0.05, Student’s t-test, n = 110-170 boutons, 3-4 animals per condition). 
We next analyzed the expression of NRG1 and Sig1R, two proteins associated with 
C-boutons (27, 39, 87, 88), in WT and Smn2B/- MNs. We had previously reported that 
NRG1 expression in spinal cord MNs dramatically decreased during the end-stages of 
disease in the SOD1G93A mouse model of ALS, but not in SMNΔ7 mice (27). On the 
other hand, reduced levels of Sig1R in lumbar MNs had been found in SOD1G93A mice, 
even during early pre-symptomatic stages (89). We used specific antibodies against 
either NRG1 or Sig1R in combination with VAChT immunostaining to detect C-
boutons. The percentage of C-boutons showing positive NRG1 was similar for both WT 
and Smn2B/- MNs at P10 and P20, but was found to significantly fall in Smn2B/- MNs at 
23 
 
P25-30 (Fig. 6J and L,M). On the other hand, the expression of Sig1R in C-boutons 
declined in Smn2B/- MNs at P20, and this reduction was maintained at P25-30 (Fig. 6K 
and O,P). It should be noted that in both WT and Smn2B/- P10 mice, Sig1R 
immunoreactivity was extensively detected in the cytoplasm of MN somata, probably 
reflecting a high density of ER membranes (Fig. 6Q); even so, only a low percentage of 
C-boutons contained Sig1R at this age (WT: ~8%, Smn2B/-: ~9%; p>0.05, Student’s t-
test, n = 110-170 synapses; 3-4 mice per condition). At P20, however, the vast majority 
of WT MNs failed to show any signs of broadly cytoplasmic Sig1R immunostaining; 
conversely, Sig1R positive profiles were seen postsynaptically associated with VAChT-
positive C-boutons. These observations are consistent with previous reports showing 
that C-bouton-associated Sig1R expression only arises after the second week of 
postnatal development (88, 90). Nevertheless, the reduction in cytoplasmic Sig1R 
normally observed at P20 did not occur in most of the MNs of Smn2B/- mice (Fig. 6R), 
apparently pointing to a defective Sig1R maturation process in SMA. A comparable 
developmental pattern of Sig1R was observed in MNs of SMNΔ7 mice (not shown). 
Overall, these results demonstrate that, although some cholinergic terminals are still 
present at later stages of SMA, they do display defects in their postsynaptic molecular 
organization, such as the reduction in NRG1 and Sig1R expression. 
Changes in the NMJs of Smn2B/- mice 
As previously reported, the NMJs of SMA mice exhibit signs of denervation, NF 
accumulation and morphological alterations that suggest a delayed synaptic maturation 
(50, 58, 60, 91-94). In severe mouse models of SMA, these alterations appear to be 
more prominent in certain muscles in the head and trunk than in those distally located in 
limbs, which frequently remain fully innervated until later stages of disease (50, 82, 94). 
To examine whether the NMJs of proximal and distal muscles of Smn2B/- mice also 
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display differential vulnerability, the proportions of NMJ denervation and NF 
accumulation were examined in IC and TA muscles of WT and Smn2B/- mice from P10 
to P25-30. To do this, muscles were immunolabeled with antibodies against NF and 
SV2 to recognize the presynaptic compartment, and then stained with α-Bgtx to identify 
the postsynaptic site. In relation to WT mice, Smn2B/- animals showed a higher 
percentage of NMJ denervation and NF accumulation in both IC and TA muscles; 
however, the NMJs of IC muscles appeared to be more severely denervated and 
exhibited abnormal NF aggregation at an earlier stage than those in TA muscles 
(supplementary Fig. 3A-D and I-P). In the IC muscles of diseased animals, a significant 
degree of denervation and NF accumulation was already evident at P10, with this being 
even more prominent at P20; in contrast, in the TA muscles of Smn2B/- mice, the number 
of NMJs exhibiting NF accumulation was not significant until P20, and then 
dramatically increased at P25-30 (the age at which significant denervation was also 
noticed). Interestingly, at P25-30 a reduction in the percentage of denervated NMJs was 
observed in IC muscles of Smn2B/- animals (supplementary Fig. 3A); this suggests that 
compensatory mechanisms of denervation could exist throughout the course of the 
disease. In fact, increased levels of axonal sprouting have been observed in the NMJs of 
different SMA mouse models (50, 60, 91, 95), including those in Smn2B/- mice ((96) and 
our own observations). The architectural analysis of postsynaptic sites also revealed that 
NMJs of both IC and TA muscles were smaller and less mature in Smn2B/- mice than in 
WT littermates, with a significant increase in the number of NMJs exhibiting a plaque 
and fold structure and a dramatic reduction in the number of those showing a perforated 
or pretzel-like (second structure) morphology (supplementary Fig. 3E-H). Overall, these 
changes also occurred at an earlier stage and were more prominent in IC than in TA 
muscles. These data, when compared with those reported in SMNΔ7 mice (50, 82, 92-
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94) in which hindlimb muscles remained innervated throughout disease progression, 
suggest that the slower the SMA progression is (as in the Smn2B/- mouse model) the 
greater is the degree of impairment in the NMJs of the distal (e.g. TA) muscles at end-
stages. 
Chronic treatment with PRE-084 did not improve lifespan or motor abilities in 
SMA mice 
We next wanted to establish whether the clinical SMA phenotype could be prevented 
or attenuated by the chronic administration of the Sig1R agonist PRE-084. To do this, 
SMNΔ7 and Smn2B/- mice, and their respective WT littermates, were daily treated with 
either PRE-084 (0.25mg/kg) or saline from P1 onwards. Body weight and survival were 
measured and a battery of tests was performed to evaluate motor function. As expected, 
SMNΔ7 and Smn2B/- mice treated with saline showed a lower growth-related gain in 
body weight than saline-injected WT animals. PRE-084 administration did not have any 
apparent influence on body weight in either of these models or phenotypes 
(supplementary Fig. 4A and Fig. 7A). The righting reflex and tube test were used to 
assess muscle strength and motor coordination in SMNΔ7 mice throughout their 
lifetime, and in Smn2B/- animals from P1 to P10. Both saline- and PRE-084-treated 
SMNΔ7 mice required similar times to right themselves on all 4 paws, demonstrating 
significant difficulties in righting themselves in comparison with saline- and PRE-084-
treated WT mice (supplementary Fig. 4B). Similarly, SMNΔ7 animals, independently of 
their treatment (either with saline or PRE-084), had shorter latencies to fall and 
registered worse scores compared to their age-matched WT mice when they were 
assessed using the tube test (supplementary Fig. 4C). As expected, no differences were 
observed between Smn2B/- animals and their WT littermates when the righting reflex and 
tube tests were performed from P1 to P10 (data not shown). From P10 onwards, the pen 
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test and the grip test were applied to assess motor abilities in the Smn2B/- model. 
Compared to WT mice, at P10, the diseased animals presented significantly shorter 
latencies to fall and lower scores in the pen test; these differences were maintained 
during the rest of the period studied. Similarly, from P16 on, the Smn2B/- animals showed 
worse performances in the grip test than the WT mice. PRE-084 administration did not 
produce any significant change in motor abilities of either WT or diseased mice. (Fig. 
7B and C). 
The Sig1R-agonist treatment was unable to prolong the lifespan of SMNΔ7 or 
Smn2B/- mice: saline- and PRE-084-treated diseased animals showed similar Kaplan-
Meier survival curves and mean survival rates (SMNΔ7-saline: 14.67 ± 1.05 days [n= 
15] and SMNΔ7-PRE-084: 14.86 ± 1.24 days [n=14], p>0.05, Student’s-t test; Smn2B/--
saline: 22.11 ± 0.87 days [n=12] and Smn2B/--PRE-084: 21.00 ± 0.79 days [n=12]; 
p>0.05, Student’s-t test) (supplementary Fig. 4D and Fig. 7D). 
PRE-084 administration did not prevent MN loss or any of the major pathological 
changes found in the NMJs of Smn2B/- mice 
We next explored whether PRE-084 treatment was able to prevent MN death in the 
Smn2B/- mouse. We restricted these experiments to this model due to the fact that, as 
previously mentioned, despite being more prominent, spinal cord MN degeneration in 
these mice is slower than in SMNΔ7 mice. Lumbar spinal cord MNs were counted in 
WT and diseased animals at P20. PRE-084 administration did not have any significant 
effect on MN numbers in Smn2B/- mice (Fig. 8A). This treatment did not improve the 
MN atrophy observed in SMA animals either (MN soma size in μm2 = Smn2B/--saline: 
379.6 ± 24.22 [n=25] and Smn2B/--PRE-084: 344.7 ± 20.29 [n=22]; p>0.05, Student’s-t 
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test). These data contrast with the reported neuroprotective effects of chronic PRE-084 
treatment in SOD1G93A mice (41). 
As MNJ alterations were more gradual and less severe in the TA muscle, this was 
used to explore the effect of PRE-084 on neuromuscular histopathology in Smn2B/- mice. 
No significant structural changes in NMJs of PRE-084-treated WT animals were 
observed in comparison with saline-injected WT mice (not shown). Chronic PRE-084 
administration mitigated the aberrant NF accumulation in nerve terminals (Fig. 8B, and 
J and N), but it did not prevent muscle denervation in diseased animals (Fig. 8C). PRE-
084 treatment neither improved the degree of atrophy nor the immaturity of Smn2B/- 
NMJs (Fig. 8D, E, and F-Q). The existence of muscle denervation despite the reduction 
in NF accumulation in the nerve terminals of PRE-084-treated SMA mice is in 
agreement with previous findings which suggest that NF aggregation does not correlate 
with NMJ vulnerability and does not predict subsequent muscle denervation (94). 
PRE-084 treatment mitigated reactive gliosis and restored the imbalance of 
microglial phenotypes associated with SMA 
Following chronic PRE-084 treatment, significant reductions in reactive astrogliosis 
and microgliosis were noted in both SMNΔ7 and Smn2B/- mouse models (Fig. 9A-J). 
When activated in neuroinflammation, microglial cells can develop to one of two 
opposing maturation states: M1 and M2 phenotypes (97-99). The M1 phenotype has 
been associated with degeneration and inflammation, while the M2 phenotype has been 
related to regenerative and anti-inflammatory processes. In neurodegenerative diseases, 
microglial cells may play either a harmful (M1 phenotype, “classical activation”) or 
beneficial (M2 phenotype, “alternative activation”) role; this depends on their intrinsic 
properties, the milieu in which they are activated, and the factors that they are 
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stimulated by (98, 99). We therefore next examined whether the inhibition of 
microgliosis by PRE-084 implied the induction of the M2 phenotype. IBA1 
immunohistochemistry was combined with Mac-2 or CD206 immunolabeling for M1 
and M2 microglia, respectively (100-102). Compared to WT animals, Smn2B/- mice were 
found to exhibit a dramatic increase in harmful M1 (Mac-2-positive) microglia and a 
significant reduction in regenerative-associated M2 (CD206-positive) cells in the spinal 
cord. PRE-084 treatment reduced the density of the Mac-2-immunoreactive profiles and 
enhanced the number of CD206-immunolabeled cells found in Smn2B/- spinal cord (Fig. 
9K and L, and M-R’’). These results indicated that the pharmacological activation of 
Sig1R prevents the M1/M2 imbalance associated with SMA. 
PRE-084 reversed the loss of synaptic afferents to MNs in Smn2B/- mice 
It had been previously shown that, in pathological conditions, activated microglial 
cells physically interact with damaged neurons and are able to remove synaptic afferents 
(reviewed in (103)). As PRE-084 prevents reactive gliosis in the spinal cord of SMA 
animals, we explored whether this agent was also able to attenuate glial-dependent MN 
deafferentation. Sections of spinal cord immunolabeled for VAChT, VGluT1 or VGAT 
were examined in order to quantify the number of positive puncta on the MN somata of 
P20 WT and Smn2B/- animals treated with either saline or the Sig1R agonist. PRE-084 
did not significantly change the density of VAChT-immunolabeled synapses compared 
to MNs of saline-treated Smn2B/- animals (Fig. 10A-D’). However, PRE-084-treated 
Smn2B/- mice showed a significant rescue of VGluT1-positive boutons (Fig. 10E-H’) and 
prevented the moderate loss of VGAT synapses (Fig. 10I-L’) resulting from disease. 
PRE-084 treatment did not modify Sig1R or NRG1 expression in the spinal cord of 
in Smn2B/- mice 
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Previous studies had reported that Sig1R agonists were able to promote their action 
by means of Sig1R upregulation via a positive-feedback mechanism (104). We therefore 
decided to examine whether chronic PRE-084 treatment modulates the expression of 
Sig1R in Smn2B/- mice (Fig. 11A-O). Western-blot analysis, used to determine Sig1R 
levels in the spinal cord, revealed no significant differences in the amount of this protein 
between the different experimental groups (Fig. 11A-B). To assess whether PRE-084 
affected Sig1R expression in MNs, we performed a double immunofluorescence with 
antibodies against Sig1R and VAChT (for C-bouton identification) on spinal cord 
sections from WT and Smn2B/- mice. PRE-084 did not modify the reduced numbers of 
C-boutons associated with Sig1R-positive profiles found in MNs of diseased animals 
(Fig. 11C-O). NRG1-positive profiles were also quantified in sections that were co-
immunostained with anti-NRG1 and anti-VAChT antibodies. MNs of PRE-084- and 
saline-treated Smn2B/- mice exhibited similar numbers of C-boutons expressing NRG1 
(Percentage of VAChT-positive boutons associated with NRG1-positive profiles: 
Smn2B/--saline = 88.67±2.39 [n = 40 MNs], Smn2B/--PRE-084 = 85.12±3.14 [n=30 MNs]; 
4 mice per group; p>0.05). 
PRE-084 treatment did not modify either the expression levels of SMN or 
modulate the NMDA receptor in the spinal cord of Smn2B/- mice 
Western blot analysis was carried out to determine whether the beneficial effects of 
PRE-084 on reactive gliosis and MN deafferentation seen in SMA were a consequence 
of an increase in the expression levels of SMN in the spinal cord. Similar low levels of 
SMN were found in extracts from diseased mice treated with either saline or PRE-084 
(Fig. 11 P,Q). A previous in vitro study using rat ganglion cells had shown that PRE-
084 modulated NMDA receptors (105). It had also been previously reported that the 
therapeutic effects of PRE-084 on SOD1G93A mice were mediated by the 
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phosphorylation of the NMDA receptor subunit NR1 at serine-896 and serine-897 (41). 
Using antibodies against NR1 and p-NR1 (Ser897), we performed western blots of 
spinal cord extracts from WT and Smn2B/- animals treated either with saline or PRE-084. 
No changes were observed in either total NR1 or p-NR1 protein levels when we 
compared samples from Smn2B/- mice treated with saline and PRE-084 (Fig. 11R-T). 
DISCUSSION 
In the present study, we used the Smn2B/- intermediate mouse model of SMA (43, 44) 
to provide a detailed characterization of the progression of the histopathological 
phenotype throughout the disease course, including: MN degeneration, defects in the 
DRG, changes in spinal cord central synapses, glial reaction and alterations in NMJs. 
The correlations of these changes with functional motor deficits were also examined. As 
C-bouton alteration and reactive gliosis were found to be prominent features in Smn2B/- 
mice, we explored the potential therapeutic effects of the Sig1R agonist PRE-084 in this 
model. The findings were then extrapolated to the SMNΔ7 mouse, a widely used severe 
model for the disease. 
Here we report that Smn2B/- mice suffer gradual and prominent MN degeneration in 
the lumbar spinal cord (>75% of the MNs present in WT animals died), starting during 
the early-presymptomatic stages of SMA; this contrasts with the moderate (~20%) MN 
loss found in severe models (Smn+/-;SMN2+/+ and SMNΔ7 mice) of the disease (49, 60). 
We also show that fast MNs are more vulnerable to degeneration in SMA than slow 
ones. Additionally, we demonstrate structural alterations in motor axons that are already 
occurring during the early-presymptomatic stages of the disease. Motor axon defects 
coincide with the onset of MN death and occur in the absence of overt pathological 
changes in the NMJs of hindlimb muscles. We also report the existence of a dramatic 
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loss of proprioceptive neurons and atrophy of both peptidergic and non-peptidergic 
nociceptive neurons in the DRG of Smn2B/- mice. Changes in DRG neurons are 
accompanied by structural defects in sensory axons and the loss of afferent inputs to 
MNs. We also show, confirming previous findings in the most severe models of SMA, 
that Smn2B/- mice display a prominent reactive gliosis in the spinal cord, which includes 
a disruption of the M1/M2 microglia phenotype. Chronic PRE-084 treatment attenuates 
reactive gliosis and restores the altered M1/M2 balance in SMA. This suggests a 
potential therapeutic effect of the Sig1R agonist by promoting M2 polarization and, in 
this way, favoring the beneficial anti-inflammatory action of microglia in SMA. This 
effect correlates with the prevention of the MN deafferentation process which takes 
place in the course of the disease. However, the beneficial effects of PRE-084 on gliosis 
and afferent inputs to MNs are not accompanied by either any improvement in lifespan 
or motor performance; PRE-084 similarly fails to prevent MN loss or to mitigate any of 
the major pathological changes present in the neuromuscular junctions of SMA mice. 
Remodeling and maturation processes occur in the central and peripheral nervous 
system during the first postnatal weeks (56, 106). Sig1R is enriched in mouse spinal 
cord MNs, in which the protein is first visualized in the ER at later stages of embryonic 
development, and then concentrates in C-boutons during the second postnatal week (88, 
90). The Sig1R location in C-boutons (88, 107) suggests the involvement of this 
receptor in the modulation of cholinergic synapses and, as a consequence of this, also in 
MN excitability and susceptibility to degeneration (20, 21, 108). We found changes in 
the normal distribution of Sig1R on MN somata and a defect in its association with C-
boutons in SMA mice; for instance, whereas at P20 the vast majority of WT MNs 
exhibited Sig1R in C-boutons with only a minimal cytoplasmic expression of this 
protein, most of the Smn2B/- MNs still displayed extensive cytoplasmic Sig1R 
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immunoreactivity. These results were, at least in part, comparable to those described in 
the wobbler mouse, a model for spontaneous MN degeneration (42). A link between 
Sig1R gene mutations and distinct neurodegenerative diseases has been reported (37, 
38). Moreover, it has been shown that Sig1R alterations may lead to MN dysfunction 
and degeneration (39, 109). Reduced levels and an abnormal distribution of Sig1R 
protein in the spinal cord of patients and mouse models for ALS have also been noticed 
(41, 110). In our work, we did not detect any altered levels of Sig1R protein in lumbar 
spinal cord extracts from Smn2B/- mice; however, by immunocytochemistry, we 
observed a reduced expression of Sig1R at C-boutons in this SMA model at P20, 
coinciding with the full symptomatic stage. This reduction in the synaptic levels of 
Sig1R persisted until the terminal stages of the disease. Even so, we did not find any 
changes in the pattern of Sig1R expression in the pre-symptomatic stages (e.g. at P10). 
These findings cannot be generically applied to MN diseases because in ALS mice 
reduced Sig1R levels have been found both in the whole spinal cord and in C-boutons 
during the early pre-symptomatic stages (41). Although we cannot rule out a role for 
Sig1R in SMA pathogenesis, the fact that the defects in the motoneuronal expression of 
this protein did not occur until advanced stages would suggest a late involvement of 
Sig1R in the neuromuscular dysfunction linked to this disease. This would explain why 
in Smn2B/- mice, MN loss (~16% of WT) had already been detected at P5, an age at 
which no significant differences in C-bouton density were found between WT and 
diseased animals. MN death continued as disease progressed, so at P10 a significant 
decrease (> 30% of WT) in the number of apparently healthy MNs was seen in SMA 
mice, but no apparent changes were noted in either the density of C-boutons or the 
number of those displaying Sig1R-positive immunolabeling. Moreover, the significant 
reduction in Sig1R expression in C-boutons on Smn2B/- MNs observed at P20 (when ~ 
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65% MNs had already been lost) was not accompanied by changes in C-bouton density 
on the remaining MNs: whereas in Smn2B/- MNs, the reduction in Sig1R expression at 
C-boutons had already been detected by P20, the loss of VAChT-labeled C-bouton 
terminals was not seen until P25-30. This indicates a dissociation in the loss of pre- 
(VAChT) and post-synaptic molecules (Sig1R) at C-boutons. The reduction in Sig1R 
expression found in C-boutons of Smn2B/- MNs is therefore an event that clearly 
precedes the loss of this type of synapse during the end-stages of the disease, when a 
large number of MNs had already died. 
Given its close proximity to Kv2.1 and to SK channels in C-boutons, Sig1R appears 
to play a role in the modulation of postsynaptic excitability and, subsequently, MN 
vulnerability. In fact, in a number of different experimental models, it has been reported 
that Sig1R can regulate the activity of Kv and SK channels (111, 112) and that Kv2.1 
and/or SK channel activation inhibits MN excitability (20, 21, 25, 113). Conversely, 
increased excitability was found in MNs exhibiting a reduction in Sig1R expression 
(107). On the other hand, Sig1R has also been involved in the regulation of Ca2+ 
homeostasis by modulating Ca2+ entry through plasma membrane (i.e. via voltage-
dependent Ca2+ channels), and Ca2+ flow from ER and to mitochondria (i.e. via inositol 
triphosphate type 3 [IP3] receptor) (28). Sig1R also appears to modulate NMDA 
receptor activity (105) and, subsequently, Ca2+ influx in neurons. In the present study, 
the activation of Sig1R by its agonist PRE-084 did not prevent MN degeneration or 
motor deterioration in Smn2B/- mice. These results contrast with the neuroprotective 
action and improvement in motor performance conferred by PRE-084 in the SOD1G93A 
(41) and wobbler (42) mouse models of MN disease. Taking into account the fact that 
these studies used similar dosages, regimens and modes of PRE-084 administration to 
the ones we used in the present work, it is possible that differences in the rates of 
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disease progression and in the pathogenic mechanisms could account for the disparities 
in the results. In fact, both disease models (SOD1G93A and wobbler mice), have a slower 
clinical outcome with a longer lifespan, and exhibited neuropathological alterations that 
start later and evolve more gradually than those in Smn2B/- mice ((46, 51, 114, 115), and 
our own observations). On the other hand, it has also been reported that PRE-084 is able 
to protect MNs against excitotoxic insults (40) and to prevent MN degeneration in 
SOD1G93A ALS mice (41) through the modulation of NMDA receptors via the protein 
kinase C (PKC) pathway. In the latter work, the authors reported a significant increase 
in the phosphorylation of NMDA-NR1 subunits in spinal cord extracts and also in MNs 
of mice treated with PRE-084 (41). These findings suggest that the neuroprotective 
action of PRE-084 could be due to a subsequent reduction in the Ca2+ permeability of 
NMDA receptors and, consequently, to a decrease in the influx of Ca2+ into MNs. We 
did not, however, detect any significant change in NR1-subunit phosphorylation, either 
by western blotting or by immunohistochemistry, in spinal cord samples from PRE-084-
treated Smn2B/- mice. Although we cannot conclude that the absence of a modulatory 
action on NMDA receptors is responsible for the lack of neuroprotection found after 
PRE-084 administration in our system, it must be taken into account that the regulation 
of intracellular Ca2+ homeostasis throughout NMDA-receptor modulation is considered 
a major mechanism through which Sig1R agonists promote neuroprotection (116, 117). 
Neuroinflammation, which involves the reactive activation of both microglia and 
astroglia, is a common process in a number of different neurodegenerative diseases, 
including ALS (118, 119). Reactive gliosis has also been described in SMA, in both 
humans (78, 79) and severe mouse models of the disease (49, 82, 120). However, the 
role of neuroinflammation in SMA pathogenesis has still to be properly elucidated. In 
fact, the glial reaction associated with neurodegenerative disorders may have either 
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deleterious (cytotoxic) or beneficial (neuroprotective) effects on MNs ((80, 99, 101) as 
reviews). Microglia are heterogeneous cells that exhibit different functional states which 
can be categorized in two opposing phenotypes: M1 (proinflammatory) and M2 
(immunosuppressive and neuroprotective). M1 microglia can turn into M2 microglia, 
and vice versa, depending on the context in which they are activated. This dynamic 
transformation of M1/M2 phenotypes appears to play a critical role in 
neurodegeneration. In pathological conditions, neuronal death has therefore been related 
to a broken balance between the two microglial (M1/M2) subpopulations as a 
consequence of the sustained activation of M1 cells (99, 101). Similarly, it has recently 
been reported that neuroinflammation can induce two different subtypes of reactive 
astrocytes: A1 and A2 (in analogy to the references used for M1 and M2 microglia), 
(121); whereas A2 astrocytes might be neuroprotective, A1 astrocytes appear to be 
detrimental and to develop neurotoxic functions following their activation by reactive 
microglia (121). Here, we show that marked microglia and astroglia activation also 
occurs in the spinal cord of Smn2B/- mice, in which phenotypic and pathological changes 
linked to SMA take place later and more gradually than in severe mouse models of the 
disease (48). We also report that microgliosis in SMA is accompanied by a significant 
increase in M1 microglia at the expense of a reduction in M2 microglia. Moreover, and 
in agreement with what has been observed in severe SMA mouse models (i.e. SMNΔ7 
mice, (49)), reactive gliosis in the spinal cord of Smn2B/- animals starts several days after 
MN degeneration and coincides with the overt loss of glutamatergic excitatory 
synapses. On the other hand, the reduction in the density of inhibitory GABAergic and 
cholinergic synapses on Smn2B/- MNs is only significant at the end-stages of the disease, 
some days after the onset of marked and sustained gliosis around degenerating neurons. 
Overall, these results extend our previous findings regarding severe mouse models of 
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SMA (49, 60) and support the assumption that microglial cells do not play an active role 
as inductors of MN degeneration in this disease. Accordingly, we have not observed any 
significant microgliosis in the spinal cord of Smn-/-;SMN2+/+ mice (a SMA model which 
is more severe than SMNΔ7) at the end-stages of the disease, coinciding with the 
maximal loss of MNs (60). It is therefore more likely that microgliosis is a secondary, 
reactive, process resulting from MN dysfunction. In this regard, we found that motor 
axons of Smn2B/- mice undergo overt histopathological changes at as early as P5; this is 
a time point at which MN loss, although present, is not yet significant and mice do not 
exhibit any apparent motor disabilities. Alterations in motor axons of P5 Smn2B/- mice 
include: swelling, hypomyelination and Wallerian-like degeneration. These changes 
may reflect a primary distal alteration (“dying-back”) or, alternatively, a secondary 
response to an earlier MN dysfunction. Whatever the case, altered MNs can create a 
pathological environment in the spinal cord which is critical for the activation of glial 
cells and promoting their physical interaction with damaged MNs (103). It is known 
that, under pathological conditions, microglia play a role not only in removing damaged 
neurons but also in detaching and engulfing altered afferent synapses, in a process 
called “synaptic stripping” (122). A similar task has also been described for astrocytes 
in actively eliminating dysfunctional synapses (123). It has been proposed that synaptic 
stripping would lead to the disconnection and removal of defective afferent inputs to 
MNs; this would form part of an attempt to protect them and to leave space to be 
subsequently occupied by healthy synaptic inputs (124). The time course of glial 
changes in SMA reported here would favor this role of removing synaptic inputs to 
MNs. It is well known that the progression of disease in SMA mouse models is 
associated with functional and structural changes in afferent synapses to MNs (27, 49, 
82-85) and that this leads to their progressive deafferentation. We, and others, have 
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previously reported that, in severe SMA mouse models (e.g. in SMNΔ7 mice), the loss 
of afferent synapses (and particularly glutamatergic inputs) starts at prenatal ages and 
precedes MN death (49, 84). Interestingly, we found here that MN deafferentation in 
Smn2B/- mice occurs during the end-stages of the disease and correlates with 
degenerative changes in DRGs and sensory nerves in the DRs. We therefore observed a 
significant loss of proprioceptive neurons expressing PV and the atrophy of nociceptive 
CGRP and IB4 positive neuronal subpopulations in the DRGs of Smn2B/- mice at P20. 
This corresponded with the point when their MNs exhibited a marked reduction in 
glutamatergic inputs but still retained their GABAergic and cholinergic afferents, which 
were not significantly reduced in number until P25-30. Importantly, despite the fact that 
MN death had already started by P5, no apparent structural signs of glutamatergic 
synapse loss were detected before P20. Although it has been reported that 
deafferentation does not contribute to MN death in SMA (113), the role of central 
synapses in the pathogenesis of this disease still remains a subject of discussion (50, 58, 
113, 125, 126). In this regard, it has been shown that abnormal MN development due to 
SMN deficiency results in both MN dysfunction and afferent input defects which can be 
corrected by expressing SMN in MNs (127). Since MN deafferentation in Smn2B/- mice 
occurs during the end-stages of the disease, in agreement with Fletcher et al.(113), we 
must conclude that the loss of synaptic afferents is not necessarily linked to MN death. 
Nevertheless, we cannot exclude the existence of an altered function in remaining 
central synapses on SMA MNs. In fact, it has been shown that a dysregulation of 
different MN synaptogenesis genes, which are required for the correct functioning of 
sensory-motor circuitry, precedes MN pathology (128). It is reasonable to consider that 
such changes in afferent input activity could have a negative impact on the integrity and 
function of MNs, thereby contributing to their progressive degeneration and favoring 
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glial reaction in SMA. It has therefore been reported that, following axotomy, 
alterations in presynaptic activity would tend to precede MN deafferentation by 
microglia, a process which appears to play a critical role in MN survival after nerve 
injury (129). 
In the central nervous system, Sig1R is not only expressed in neurons, but also in 
microglial cells (130) and astrocytes (131). Sig1R stimulation in vitro has been found to 
modulate multiple aspects of microglial activity (including the morphological, 
migratory and inflammatory responses) (36, 132, 133) and also the inflammatory 
reaction to several known macrophage activators in the peripheral immune system 
(134). Sig1R agonists have also been reported to attenuate astrogliosis in a rodent model 
for stroke injury (135), and to regulate astrocytic activity (136) and the expression of 
neurotrophic factors following MN injury (34). Here, we show that PRE-084 was able 
to prevent reactive gliosis in both of the mouse models for SMA (SMNΔ7 and Smn2B/- 
mice) used in the study. We also found that PRE-084 restored the microglial phenotype 
(M1/M2) balance altered by the disease. This result is in agreement with the previously 
reported action of PRE-084 counteracting the M1/M2 imbalance in the wobbler mouse 
(42). However, contrasting with this finding, the beneficial effect of PRE-084 on 
neuroinflammation in our model was not accompanied by the prevention of MN 
degeneration. Nevertheless, we noticed that the Sig1R agonist was able to mitigate the 
loss of the synaptic inputs that occur in MNs during SMA progression. Overall, these 
data suggest that the activation of glial Sig1Rs can inhibit the synaptic stripping process 
resulting from reactive gliosis and show that the prevention of MN deafferentation is 
not sufficient to inhibit neurodegeneration in SMA. It has been reported that deficient 
levels of SMN result in intrinsic changes in the functional properties of MNs, which 
show higher excitability than under normal conditions (85, 137). Moreover, the 
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restoration of SMN in MNs appears to be necessary for the rescue of 
electrophysiological deficits in SMA (138). Our results therefore show that the 
prevention of gliosis and MN deafferentation, resulting from activation of Sig1Rs in the 
absence of SMN expression in MNs, is not sufficient to promote MN survival or 
improve motor abilities in SMA. However, pharmacological targeting of glial activation 
and central synaptic loss should not be neglected as a complementary therapy in 
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Figure 1. MN degeneration in Smn2B/- mice. A, B) Time-course of MN loss (A) and MN 
atrophy (B) in the lumbar spinal cord of Smn2B/- mice during disease progression; MN 
counts and soma area measurements were performed in serial paraffin sections obtained 
through the entire lumbar segment of spinal cord. MN death (A) in Smn2B/- animals is 
already observed at P5, but does not become significant until P10; a dramatic reduction 
(~75% of WT) in the number of MNs is seen at P20 in Smn2B/- animals, with negligible 
additional MN death from P20 to P25-30. MN death in Smn2B/- mice is accompanied by 
marked atrophy (expressed as a reduction in the soma area) in surviving MNs, which is 
already significant at P5. C-G) Representative images of H&E stained MNs present in 
the ventral horn of lumbar spinal cord of mice used for cell counting. Note in (E) the 
almost complete disappearance of MNs in the spinal cord of a Smn2B/- mouse at the end-
stage of disease (P28); contrasting with healthy MNs in WT mice (C and D), some 
remaining MNs in Smn2B/- animals displayed prominent atrophy and loss of basophilia 
(arrows in E and F). Degenerating Smn2B/- MNs were frequently surrounded by nuclear 
profiles presumably corresponding to recruited microglia contacting cell bodies. H) 
Percentage of spinal MNs displaying MMP-9-positive immunoreactivity in WT and 
Smn2B/- mice at different postnatal ages; a significant reduction in the number of MNs 
expressing MMP-9 (as a marker of the fast MN subtype) can already be observed in 
SMA animals at P5; the decrease in the percentage of MNs expressing MMP-9 is even 
more marked in advanced stages of disease. I-N’) Representative images of lumbar 
spinal cord sections processed for immunocytochemistry to detect MMP-9 expression 
(green) in Smn2B/- and WT MNs at different postnatal ages; sections were counterstained 
with fluorescent Nissl staining (red). Note the reduction in MMP-9 levels observed in 
MNs of Smn2B/- animals at all ages, but particularly at P20. The data in the graph are 
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expressed as mean ± SEM, *p<0.05, **p<0.01 and ***p<0.001 vs. WT (two-way 
ANOVA, Bonferroni’s post-hoc test); n = 4-8 mice per age and condition in (A) and 
(B); n = 100-240 MNs of 3-4 animals per age and condition in (C). Scale bars: E = 100 
μm, (valid for C), F = 25 μm (valid for D), G = 10 μm, J’ = 100 μm (valid for I-J), L’ = 
30 μm (valid for K-L), N’ = 20 μm (valid for M-N). 
Figure 2. Changes in motor axons of Smn2B/- mice. A) Diameter (in μm) of myelinated 
axons (including myelin sheath) in L4 VRs of WT and Smn2B/- mice at different 
postnatal ages. B) Relative frequency of myelinated axon diameter in L4 VRs of WT 
and Smn2B/- mice at P25-30; in WT VRs there is a clear bimodal profile indicative of 
axons originating from ߙ-MNs (large axons) and ߛ-MNs (small axons); note in Smn2B/- 
VRs a selective reduction in the percentage of large axons at the expense of the 
increased number of small axons. C) Number of degenerating motor axons in L4 VRs 
of WT and Smn2B/- mice at different postnatal ages. D-K) Representative images taken 
from semithin cross sections of L4 VRs from WT and Smn2B/- mice at different time 
points. Sections were stained with methylene blue for myelin and axon degeneration 
analysis. Arrows in (G), (I) and (K) indicate degenerating motor axons. L) Percentage 
of motor axons exhibiting myelin balls in L4 VRs of P5 WT and Smn2B/- mice. M) 
Representative images of methylene blue-stained semithin cross sections of VRs from 
P5 Smn2B/- mice used for the counts shown in (L); arrows indicate myelin balls inside 
some motor axons (seen at higher magnification in the inset). The data in the graph are 
expressed as mean ± SEM; *p<0.05, **p<0.01 and ***p<0.001 vs. WT (two-way 
ANOVA, Bonferroni’s post-hoc test in [A] and [C], and Student’s t-test in [L]; n = 3-5 
L4 VRs from different mice per age and condition). Scale bars = 20 μm in K (valid for 
D-J) and in M; 50 μm in M inset. 
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Figure 3. Ultrastructural analysis of motor axon alterations in Smn2B/- mice. A-F) 
Representative electron micrographs of L4 VRs of WT (A and B) and Smn2B/- (C-F) 
animals at P5. A) The red arrow indicates a normal Schwann cell enwrapping a healthy 
motor axon in a WT animal. B) The yellow arrow shows one of the very few 
degenerating axons seen in WT VRs, indicative of a physiological remodeling process 
during the early postnatal period. C) The blue arrow indicates a focal disorganization of 
myelin lamellae, which results in a multilamellar myelin ball compressing an axon. D) 
The asterisk indicates a swollen axon enwrapped by a thin myelin sheath; another 
degenerating axon is indicated by the blue arrow. E) The asterisk indicates a motor axon 
enwrapped by a non-myelinating Schwann cell. F) A motor axon in an advanced stage 
of degeneration is indicated by the blue arrow. G) Diameter (in μm) of motor axons in 
L4 VRs from P5 WT and Smn2B/- mice, showing a significant increase in the axon size 
of diseased animals; the measurements were performed by delineating the axon 
periphery under the myelin sheath. H, I) Quantification of myelin thickness by g-ratio 
analysis (H) and scatter plot (I) depicting g-ratios in relation to axon diameter in VRs 
from P5 WT and Smn2B/- animals; note that Smn2B/- animals have motor axons with 
increased g-ratios (indicative of thinner myelin sheaths, H), and that these axons 
correspond to those with greater diameters (I). All the measurements were performed on 
electron micrographs taken from ultrathin cross sections of L4 VRs at comparable 
levels. The data in the graphs are expressed as mean ± SEM, ***p<0.001 (Student’s t-
test) vs. WT; n = 3 L4 VRs from different animals per condition. Scale bar in E = 1 μm 
(valid for A-D), and in F = 0.5 μm. 
Figure 4. Changes in DRG sensory neurons of Smn2B/- mice. A, B) Neuron size (A) 
(expressed as the soma area in μm2) and relative frequency distribution of sensory 
neuron size (B) in L4 DRG of WT and Smn2B/- mice at P20. C-K) Percentage (C, F and 
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I) and soma area (D, G and J) of sensory neurons expressing CGRP (C and D), IB4 (F 
and G) and PV (I and J) in the L4 DRG of WT and Smn2B/- mice at P20. E, H, K) 
Relative size-frequency (expressed as soma area in μm2) histogram of DRG neurons 
showing CGRP (E), IB4 (H) and PV (K) positive staining. L-K’’) Representative 
micrographs taken from DRG cryostat sections processed for CGRP, IB4 and PV 
staining (green), as indicated. Sections were also counterstained with fluorescent Nissl 
staining (red). The data in the graphs are expressed as mean ± SEM; *p<0.05 and 
***p<0.001 (Student’s t-test) vs. WT; n = 410-620 neurons counted on 21-26 DRG 
sections (4 mice per condition). Scale bar in M’’, O’’ and K’’ = 50 μm (valid for L-M’, 
N-O’ and P-K’, respectively). 
Figure 5. Changes in sensory axons in Smn2B/- mice. The analysis was performed on L4 
DRs. A) Area of DRs (in μm2) from WT and Smn2B/- mice at different postnatal ages; n 
= 3-5 DRs from different mice and conditions. B, C) Representative images taken from 
methylene blue-stained semithin cross sections of DRs from P30 WT (B) and Smn2B/- 
(C) mice used for the counts shown in (A). D-F) Number (D) and diameter (E) of 
axons, and relative frequency distribution (F) of axon size in DRs from P25-30 WT and 
Smn2B/- mice; n = 250-300 axons of DRs from 3-4 different animals per condition. G, 
H) Representative images showing the appearance of sensory axons analyzed in (D-F). 
All data are expressed as mean ± SEM; *p<0.05, **p<0.01 and ***p<0.001 vs. WT 
(two-way ANOVA, Bonferroni’s post-hoc test [A] and Student’s t-test [D-F]); Scale bar 
in C = 50 μm (valid for B) and in H = 20 μm (valid for G). 
Figure 6. Changes in C-boutons on lumbar spinal cord MNs of Smn2B/- mice. A) 
Density of C-boutons (VAChT-positive puncta) on MNs of WT and Smn2B/- mice at 
different postnatal ages; C-bouton density was calculated after normalization of the 
synapse number to 100 μm of MN soma perimeter. B-I) Representative confocal 
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micrographs of VAChT-immunoreactive synaptic boutons (green) in the spinal cord 
ventral horn of WT (B-H) and Smn2B/- (C-I) mice at different ages. Fluorescent Nissl 
staining (blue) was used for MN identification. J,K) Percentage of VAChT-positive 
boutons associated with NRG1- (J) and Sig1R- (K) positive profiles in spinal MNs of 
WT and Smn2B/- animals at different postnatal days. L-P) Representative confocal 
micrographs of spinal cord sections processed for double-immunostaining to visualize 
VAChT (green) and either NRG1 (L,M) or Sig1R (O,P) (red) in MNs of WT (L,O) and 
Smn2B/- (M,P) at P20 and P30; fluorescent Nissl staining was used for MN identification 
(blue); Q,R) Confocal images showing the pattern of Sig1R immunoreactivity in MNs 
of Smn2B/- mice at P10 (Q) and P20 (R): a broad cytoplasmic Sig1R expression is 
present in the vast majority of Smn2B/- MNs at P10 (Q); this pattern of Sig1R 
immunostaining, which is downregulated under the control conditions, is still 
maintained in a high proportion of MNs in P20 Smn2B/- animals (R). To improve Sig1R 
visualization settings for red channel were modified in (Q) and (R). The data in the 
graphs are expressed as mean ± SEM; n = 30-60 MNs per mice and condition (3-4 
animals per age and experimental group); *p<0.05 and ***p<0.001 (two-way ANOVA, 
Bonferroni’s post-hoc test) vs. WT. Scale bar: 20 μm in I (valid for B-H) and R (valid 
for L-Q). 
Figure 7. Chronic treatment with PRE-084 does not improve lifespan or motor abilities 
in Smn2B/- mice. A-C) Body weight curve (A), and pen and (B) grip (C) tests performed 
on WT and Smn2B/- animals treated with either saline or PRE-084. Values are shown as 
mean ± SEM, n = 10-12 mice per condition; no significant differences in body weight, 
or pen and grip test performance were observed between saline- and PRE-084-treated 
Smn2B/- animals (two-way ANOVA, Bonferroni’s post-hoc test). D) Kaplan-Meier 
survival curve for the different experimental groups. Saline- and PRE-084-injected 
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Smn2B/- mice do not show any significant differences in mean survival (22.11 ± 0.87 and 
21.00 ± 0.79 days, respectively; p>0.05, Student’s t-test, n = 12 animals per condition). 
Since no significant differences were observed between saline- and PRE-084 treated 
WT mice in any of the tests used to assess motor behavior, data from the PRE-084 WT 
group were excluded to simplify the graphs. 
Figure 8. PRE-084 administration does not mitigate MN loss or major pathological 
changes in NMJs of Smn2B/- mice. The data in the graphs, expressed as mean ± SEM, 
were obtained from the lumbar spinal cord and TA muscles of P20 WT and Smn2B/- 
mice chronically treated with either saline or PRE-084. A) Number of apparently 
healthy MNs in the entire lumbar segment of spinal cord from 5-6 animals per 
condition. B-E) show: percentage of NMJs with NF accumulation in nerve terminals 
(B), percentage of NMJs exhibiting different degrees of innervation (based on the 
proportion of α-Bgtx labeled postsynaptic site area covered by SV2-immunostained 
presynaptic terminals, C), NMJ size (in μm2, D), and percentage of NMJs showing 
different degrees of maturity based on the morphology of the postsynaptic site (plaque, 
folds, perforations or secondary structure [pretzel-like], E); note that the only significant 
beneficial change induced by PRE-084 in NMJs of Smn2B/- animals was the alleviation 
of NF aggregation in the nerve terminals. Analyses were performed in 50-75 NMJs of 
TA muscles from 4 animals per condition; ***p<0.001 (one-way ANOVA, 
Bonferroni’s post-hoc test). F-Q) Representative confocal images illustrating the results 
shown in (B-E); cryostat sections of TA muscles were immunolabeled with antibodies 
against NF (blue) and SV2 (red), and stained with α-Bgtx (green) to identify 
postsynaptic sites. The white arrow in (J) indicates NF aggregates in a NMJ of a Smn2B/- 
mouse; yellow arrows in (K) and (O) indicate denervated NMJs displaying negative 
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immunostaining for SV2. Dotted lines delineate NMJs. Scale bar in Q = 20 μm (valid 
for F-M). 
Figure 9. Chronic PRE-084 administration prevents reactive gliosis and restores the 
microglia phenotype imbalance associated with SMA. A-D) Quantification of GFAP-
positive astroglia (A and C) and IBA1-positive microglia (B and D) around MNs in the 
ventral horn of lumbar spinal cord from P7-8 SMNΔ7 (A and B) and P20 Smn2B/- (C 
and D) mice and their respective WT littermates. E-J) Representative confocal 
micrographs taken from spinal cord sections of WT and Smn2B/- used for data analysis in 
(C) and (D); cryostat sections were immunolabeled with antibodies against GFAP and 
IBA1, (both in green) and counterstained with fluorescent Nissl stain (red); note the 
significant reduction in both GFAP and IBA1 immunoreactivity around MNs of Smn2B/- 
animals after PRE-084 treatment. K,L) Quantification of Mac-2-positive (K) and 
CD206-positive (L) immunostaining in the lumbar spinal cord of animals belonging to 
different experimental groups; note that the significant increase in the number Mac-2-
positive (M1) microglia and decrease in CD206-positive (M2) microglia observed in 
Smn2B/- animals is prevented by PRE-084 treatment. M-R’’) Representative confocal 
micrographs used for data analysis shown in (K) and (L); cryostat sections of lumbar 
spinal cord from WT and Smn2B/- mice, treated with either saline or PRE-084, were 
processed for immunocytochemistry with antibodies against IBA1 (green) and either 
Mac-2 or CD206 (red); arrows in (P’), (Q’) and (R’) indicate CD206-positive cells 
located in the periphery of the spinal cord white matter, as previously reported (42); 
note that the number of these cells decreases in sections of Smn2B/- mice; this change is 
restored after PRE-084 treatment. Dotted and dashed lines in pictures delimitate the 
boundaries of gray matter and white matter (spinal cord section periphery), respectively. 
The data in the graphs are expressed as mean ± SEM; n = 4 animals per condition in 
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each genotype; *p<0.05, **p<0.01 and ***p<0.001 (one-way ANOVA, Bonferroni’s 
post-hoc test). Scale bars =200 μm in G and J (valid for E and F, and H-I, 
respectively), and in R’’ (valid for M-R’). 
Figure 10. PRE-084 treatment prevents deafferentation of spinal cord MNs in Smn2B/- 
mice. A-L’) Number of VAChT (A), VGluT1 (E) and VGAT (I) puncta apposed to WT 
and Smn2B/- MNs (per 100 μm of soma perimeter) following either saline or PRE-084 
injections. The data in the graphs are expressed as mean ± SEM. Counts were 
performed in 25-40 MNs per mouse (4 animals per condition); *p<0.05 and **p<0.01 
(one-way ANOVA, Bonferroni’s post-hoc test). Representative confocal images of data 
included in (A), (E) and (I) are shown on the right of the graphs; images were taken 
from sections of lumbar spinal cord processed for immunocytochemistry with 
antibodies against VAChT (B-D’), VGluT1 (F-H) and VGAT (J-L’) (all in green) and 
counterstained with fluorescent Nissl stain (blue). Scale bar in L’ = 20 μm (valid for B-
D’, F-H’, and J-L).  
Figure 11. PRE-084 treatment neither modifies Sig1R and SMN protein levels nor 
modulates NMDA receptor in the spinal cord of Smn2B/- mice. Spinal cords of WT and 
diseased animals, treated with either saline or PRE-084, were collected at P20 for 
analysis. A) Representative western blots for Sig1R and β-actin (as a loading control). 
B) Quantification by densitometry of Sig1R levels in western blots performed on 
samples from different conditions. The data are expressed as the percentage of change 
in relation to the levels found in the WT-saline group. C) Percentage of VAChT-
positive boutons showing a spatial relationship with Sig1R-positive profiles. D-O) 
Representative confocal images taken from spinal cord sections double immunolabeled 
with antibodies against VAChT (green) and Sig1R (red) and counterstained with 
fluorescent Nissl stain for MN identification (blue). P-T) PRE-084 treatment does not 
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modify either SMN or NMDA-receptor levels in the spinal cord of Smn2B/- mice. P) 
Representative western blot for SMN and β-actin (as a loading control) in the spinal 
cord of mice belonging to different groups. Q) Densitometry analysis of SMN protein 
levels in western blots; data are shown as the percentage of change in relation to the 
ratio of SMN to β-actin of saline-treated WT mice. R) Representative western blot for 
NR1, p-NR1 and β-actin (as loading control) in the spinal cord. S,T) Densitometry 
analysis of NR1 (S) and p-NR1 (T) protein levels in western blots; the data are shown 
as the percentage of change in relation to the ratio of either NR1 or p-NR1 to β-actin in 
the saline-treated WT group. The data in the graph are expressed as mean ± SEM and 
obtained from 3 mice per condition; **p<0.01 and ***p<0.001 (one-way ANOVA, 
Bonferroni’s post-hoc test). Scale bar in O = 10 μm (valid for D-N). 
Supplementary Figures 
Supplementary Figure 1. A-E) Battery of tests used to assess the motor phenotype in 
Smn2B/- mice and their respective age-matched WT littermates, as indicated. A) Smn2B/- 
and WT mice show similar body weights until P10, but thereafter Smn2B/- animals 
exhibit smaller sizes and significantly lower weights than their WT littermates, 
indicative of a reduced growth rate linked to the disease. Righting reflex (B) and tube 
test (latency to fall in seconds [C]) performed from P1 to P10 (the ideal animal age 
range for these tests (53)) does not show apparent differences between WT and Smn2B/- 
animals. Pen (D) and grip (E) tests, performed to assess motor balance and muscular 
strength, reveal significant differences between WT and Smn2B/- mice from P12-P14 
onwards. In all the graphs, values are shown as mean ± SEM and two-way ANOVA 
(Bonferroni’s post-hoc test) was used for statistical analysis (n=10-15 mice per 
experimental group); **p<0.01 and ***p<0.001 vs. WT. 
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Supplementary Figure 2. A-H) Changes in GFAP and IBA1 immunoreactivity in the 
spinal cord of Smn2B/- mice. A,B) Quantification of GFAP (for astroglia [A]) and IBA1 
(for microglia [B]) immunoreactivity in the ventral horn of lumbar spinal cord of WT 
and Smn2B/- mice at different postnatal ages; bars in graphs represent the percentage of 
positive immunoreactivity change in the ventral horn of Smn2B/- mice with respect to 
age-matched WT animals. Image analysis was performed in 15-30 sections per 
condition (3-4 animals per age and genotype); the data are expressed as mean ± SEM; 
**p<0.01 and ***p<0.001 (one-way ANOVA, Bonferroni’s post-hoc test) vs. WT mice. 
C-H) Representative confocal micrographs used for the analysis shown in (A) and (B); 
sections were processed for immunocytochemistry using antibodies against GFAP (C 
and D) or IBA1 (E-H) (both in green), and counterstained with fluorescent Nissl stain 
(red); micrographs from P20 and P30 spinal cords are shown. I-V) Changes in VGluT1 
and VGAT afferent inputs to MNs in Smn2B/- mice. I, P) Numbers of VGluT1- (I) and 
VGAT- (P) positive boutons (puncta) on MNs (per 100 μm soma perimeter) in the 
lumbar spinal cord of WT and diseased animals at indicated postnatal ages. Bars in 
graphs represent the percentage of bouton density change in the ventral horn of Smn2B/- 
mice with respect to age-matched WT animals; n = 40-55 MNs per mouse and condition 
(3-4 animals per age and experimental group). The data are expressed as mean ± SEM; 
*p<0.05, **p<0.01 and ***p<0.001 (one-way ANOVA, Bonferroni’s post-hoc test) vs. 
WT mice. J-V) Representative confocal micrographs of VGluT1- (J-O) and VGAT- 
(Q-N) immunoreactive synaptic boutons (green) in the spinal cord ventral horn of WT 
(J-L and Q-S) and Smn2B/- (M-O and T-V) mice; MNs were identified following 
fluorescent Nissl staining (red). Scale bar: in D and H= 200 μm (valid for C and E-F, 
respectively) and V = 20 μm (valid for J-U). 
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Supplementary Figure 3. Progression of NMJ pathology in Smn2B/- mice. Pre- and 
post-synaptic morphology were examined in NMJs of IC and TA muscles at different 
postnatal ages. A,B) Percentage of innervated NMJs in IC (A) and TA (B) muscles. 
C,D) Number of NMJs showing NF aggregates in IC (C) and TA (D) muscles. E,F) 
Size (in μm2) of NMJs in IC (E) and TA (F) muscles. G,H) Percentage of NMJs 
exhibiting a mature appearance, assessed by the pretzel-like morphology of the 
postsynaptic site, in IC (G) and TA (H) muscles; note the significant reduction in the 
number of mature (pretzel-like) NMJs in both muscles but particularly in IC muscles, in 
which changes reflecting NMJ immaturity occur earlier and more prominently than in 
TA muscles. G-L) Representative images illustrating the results shown in (A-H); 
cryostat muscle sections were immunolabeled with antibodies against SV2 and NF 
(blue), and stained with α-Bgtx (green). I-K) show the appearance of healthy NMJs in 
IC muscles of P10 (I-J) and P30 (K) WT mice. L and M) show a denervated NMJ (L) 
and NF accumulation in the nerve terminal of an innervated NMJ (arrow in M) in IC 
muscles from P10 Smn2B/- mice; an innervated NMJ in the IC muscle of a Smn2B/- mouse 
is depicted in (N); note that although the NMJ has an almost normal appearance, its 
postsynaptic site is reduced in size. O-P) show NMJs in the TA muscle from P20 WT 
(O) and Smn2B/- (P) mice; note the pretzel-like morphology (indicative of maturity) of 
the NMJ in (O), and the plaque morphology and dramatic reduction in size of the NMJ 
in (P). The data in the graphs are expressed as mean ± SEM; n = 60-90 NMJs in IC and 
TA muscles of 3-4 different animals per condition; *p<0.05, **p<0.01, and ***p<0.001 
(two-way ANOVA, Bonferroni’s post-hoc test). Scale bar: 10 μm in P (valid for I-O). 
Supplementary Figure 4. Chronic treatment with PRE-084 does not improve the motor 
abilities or lifespan of SMNΔ7 mice. A-C) Body weight curve (A), and righting reflex 
and (B) tube test (C) performed on WT and SMNΔ7 animals treated with either saline 
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or PRE-084. Values are shown as mean ± SEM, n = 15-20 mice per condition; no 
significant differences in body weight, righting reflex or tube test performance were 
observed between saline- and PRE-084-treated SMNΔ7 animals (two-way ANOVA, 
Bonferroni’s post-hoc test). D) Kaplan-Meier survival curve for the different 
experimental groups. Saline- and PRE-084-injected SMNΔ7 mice does not show any 
significant differences in mean survival (14.67 ± 1.05 days [n= 15]; SMNΔ7-PRE-084: 
14.86 ± 1.24 days [n=14]; p>0.05, Student’s t-test). Since no significant differences 
were observed between saline- and PRE-084 treated WT mice in any of the tests used 
for motor behavior examination, data from the PRE-084 WT group were excluded to 
simplify the graphs. 
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